Literature DB >> 22547072

Conformational differences between two amyloid β oligomers of similar size and dissimilar toxicity.

Ali Reza A Ladiwala1, Jeffrey Litt, Ravi S Kane, Darryl S Aucoin, Steven O Smith, Swarnim Ranjan, Judianne Davis, William E Van Nostrand, Peter M Tessier.   

Abstract

Several protein conformational disorders (Parkinson and prion diseases) are linked to aberrant folding of proteins into prefibrillar oligomers and amyloid fibrils. Although prefibrillar oligomers are more toxic than their fibrillar counterparts, it is difficult to decouple the origin of their dissimilar toxicity because oligomers and fibrils differ both in terms of structure and size. Here we report the characterization of two oligomers of the 42-residue amyloid β (Aβ42) peptide associated with Alzheimer disease that possess similar size and dissimilar toxicity. We find that Aβ42 spontaneously forms prefibrillar oligomers at Aβ concentrations below 30 μm in the absence of agitation, whereas higher Aβ concentrations lead to rapid formation of fibrils. Interestingly, Aβ prefibrillar oligomers do not convert into fibrils under quiescent assembly conditions but instead convert into a second type of oligomer with size and morphology similar to those of Aβ prefibrillar oligomers. Strikingly, this alternative Aβ oligomer is non-toxic to mammalian cells relative to Aβ monomer. We find that two hydrophobic peptide segments within Aβ (residues 16-22 and 30-42) are more solvent-exposed in the more toxic Aβ oligomer. The less toxic oligomer is devoid of β-sheet structure, insoluble, and non-immunoreactive with oligomer- and fibril-specific antibodies. Moreover, the less toxic oligomer is incapable of disrupting lipid bilayers, in contrast to its more toxic oligomeric counterpart. Our results suggest that the ability of non-fibrillar Aβ oligomers to interact with and disrupt cellular membranes is linked to the degree of solvent exposure of their central and C-terminal hydrophobic peptide segments.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22547072      PMCID: PMC3397903          DOI: 10.1074/jbc.M111.329763

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  37 in total

1.  Cerebrospinal fluid beta-amyloid(1-42) in Alzheimer disease: differences between early- and late-onset Alzheimer disease and stability during the course of disease.

Authors:  N Andreasen; C Hesse; P Davidsson; L Minthon; A Wallin; B Winblad; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  Arch Neurol       Date:  1999-06

2.  Common structure of soluble amyloid oligomers implies common mechanism of pathogenesis.

Authors:  Rakez Kayed; Elizabeth Head; Jennifer L Thompson; Theresa M McIntire; Saskia C Milton; Carl W Cotman; Charles G Glabe
Journal:  Science       Date:  2003-04-18       Impact factor: 47.728

3.  Aromatic small molecules remodel toxic soluble oligomers of amyloid beta through three independent pathways.

Authors:  Ali Reza A Ladiwala; Jonathan S Dordick; Peter M Tessier
Journal:  J Biol Chem       Date:  2010-11-23       Impact factor: 5.157

4.  A causative link between the structure of aberrant protein oligomers and their toxicity.

Authors:  Silvia Campioni; Benedetta Mannini; Mariagioia Zampagni; Anna Pensalfini; Claudia Parrini; Elisa Evangelisti; Annalisa Relini; Massimo Stefani; Christopher M Dobson; Cristina Cecchi; Fabrizio Chiti
Journal:  Nat Chem Biol       Date:  2010-01-10       Impact factor: 15.040

Review 5.  Amyloid oligomers: formation and toxicity of Abeta oligomers.

Authors:  Masafumi Sakono; Tamotsu Zako
Journal:  FEBS J       Date:  2010-02-09       Impact factor: 5.542

6.  Role of aggregation conditions in structure, stability, and toxicity of intermediates in the Abeta fibril formation pathway.

Authors:  Sungmun Lee; Erik J Fernandez; Theresa A Good
Journal:  Protein Sci       Date:  2007-02-27       Impact factor: 6.725

7.  Vaccination with soluble Abeta oligomers generates toxicity-neutralizing antibodies.

Authors:  M P Lambert; K L Viola; B A Chromy; L Chang; T E Morgan; J Yu; D L Venton; G A Krafft; C E Finch; W L Klein
Journal:  J Neurochem       Date:  2001-11       Impact factor: 5.372

Review 8.  A beta oligomers - a decade of discovery.

Authors:  Dominic M Walsh; Dennis J Selkoe
Journal:  J Neurochem       Date:  2007-02-05       Impact factor: 5.372

9.  Anti-oligomeric Abeta single-chain variable domain antibody blocks Abeta-induced toxicity against human neuroblastoma cells.

Authors:  Andleeb Zameer; Srinath Kasturirangan; Sharareh Emadi; Sridevi V Nimmagadda; Michael R Sierks
Journal:  J Mol Biol       Date:  2008-10-07       Impact factor: 5.469

10.  The effect of macromolecular crowding on protein aggregation and amyloid fibril formation.

Authors:  Larissa A Munishkina; Elisa M Cooper; Vladimir N Uversky; Anthony L Fink
Journal:  J Mol Recognit       Date:  2004 Sep-Oct       Impact factor: 2.137

View more
  80 in total

1.  Transthyretin-derived peptides as β-amyloid inhibitors.

Authors:  Patricia Y Cho; Gururaj Joshi; Jeffrey A Johnson; Regina M Murphy
Journal:  ACS Chem Neurosci       Date:  2014-04-09       Impact factor: 4.418

2.  Aggregation modulators interfere with membrane interactions of β2-microglobulin fibrils.

Authors:  Tania Sheynis; Anat Friediger; Wei-Feng Xue; Andrew L Hellewell; Kevin W Tipping; Eric W Hewitt; Sheena E Radford; Raz Jelinek
Journal:  Biophys J       Date:  2013-08-06       Impact factor: 4.033

3.  Successive Stages of Amyloid-β Self-Assembly Characterized by Solid-State Nuclear Magnetic Resonance with Dynamic Nuclear Polarization.

Authors:  Alexey Potapov; Wai-Ming Yau; Rodolfo Ghirlando; Kent R Thurber; Robert Tycko
Journal:  J Am Chem Soc       Date:  2015-06-19       Impact factor: 15.419

Review 4.  The neurodegeneration in Alzheimer disease and the prion protein.

Authors:  Gianluigi Forloni; Alessandra Sclip; Tiziana Borsello; Claudia Balducci
Journal:  Prion       Date:  2013-01-01       Impact factor: 3.931

5.  Pretreatment of chemically-synthesized Aβ42 affects its biological activity in yeast.

Authors:  Afsaneh Porzoor; Joanne M Caine; Ian G Macreadie
Journal:  Prion       Date:  2014       Impact factor: 3.931

Review 6.  Exploring the accessible conformations of N-terminal acetylated α-synuclein.

Authors:  Gina M Moriarty; Maria K Janowska; Lijuan Kang; Jean Baum
Journal:  FEBS Lett       Date:  2013-03-13       Impact factor: 4.124

7.  Pathogenic serum amyloid A 1.1 shows a long oligomer-rich fibrillation lag phase contrary to the highly amyloidogenic non-pathogenic SAA2.2.

Authors:  Saipraveen Srinivasan; Sanket Patke; Yun Wang; Zhuqiu Ye; Jeffrey Litt; Sunit K Srivastava; Maria M Lopez; Dmitry Kurouski; Igor K Lednev; Ravi S Kane; Wilfredo Colón
Journal:  J Biol Chem       Date:  2012-12-05       Impact factor: 5.157

Review 8.  Alzheimer's disease: which type of amyloid-preventing drug agents to employ?

Authors:  Hyunbum Jang; Laura Connelly; Fernando Teran Arce; Srinivasan Ramachandran; Ratnesh Lal; Bruce L Kagan; Ruth Nussinov
Journal:  Phys Chem Chem Phys       Date:  2013-02-28       Impact factor: 3.676

Review 9.  Differences between amyloid-β aggregation in solution and on the membrane: insights into elucidation of the mechanistic details of Alzheimer's disease.

Authors:  Samuel A Kotler; Patrick Walsh; Jeffrey R Brender; Ayyalusamy Ramamoorthy
Journal:  Chem Soc Rev       Date:  2014-10-07       Impact factor: 54.564

10.  Intrahippocampal administration of a domain antibody that binds aggregated amyloid-β reverses cognitive deficits produced by diet-induced obesity.

Authors:  Danielle M Osborne; Dennis P Fitzgerald; Kelsey E O'Leary; Brian M Anderson; Christine C Lee; Peter M Tessier; Ewan C McNay
Journal:  Biochim Biophys Acta       Date:  2016-03-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.